Key result
PCSK9 inhibitor price cuts failed to meaningfully boost Medicare Part D utilization or spending.
Answers are grounded in this paper and cite their sources.
This study evaluates the impact of price reductions on Medicare Part D utilization and spending for PCSK9 inhibitors.
This cross-sectional study evaluates price reductions and subsequent Medicare Part D utilization and spending for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
No takes yet. Share an insight, caveat, or question.
Doshi et al. (2026) studied this question. PCSK9 inhibitor price reductions were evaluated to determine their impact on subsequent Medicare Part D utilization and spending.
Synapse has enriched 10 related papers. Consider them for comparative context: